Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial

Alan K. Burnett(Cardiff University), Donald Milligan(National Health Service), Nigel H. Russell(Guy's and St Thomas' NHS Foundation Trust), Robert K. Hills(Cancer Research UK Clinical Trials Unit), Ann E. Hunter(National Health Service), Brenda Gibson(Royal Hospital for Children), Lars Kjeldsen(Copenhagen University Hospital), John Liu Yin(National Health Service), Keith Wheatley(Cancer Research UK Clinical Trials Unit)
Journal of Clinical Oncology
August 12, 2013
10.1200/jco.2012.47.4874
Cited by 415

Related Papers

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
|Blood|2009|3.4k
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
|Blood|2010|1.9k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
|Blood|2008|957
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)
|Blood|2007|782